Bibliographic Details
| Title: |
Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. |
| Authors: |
Asaoka, Daisuke, Xiao, Jinzhong, Takeda, Tsutomu, Yanagisawa, Naotake, Yamazaki, Takahiro, Matsubara, Yoichiro, Sugiyama, Hideki, Endo, Noemi, Higa, Motoyuki, Kasanuki, Koji, Ichimiya, Yosuke, Koido, Shigeo, Ohno, Kazuya, Bernier, Francois, Katsumata, Noriko, Nagahara, Akihito, Arai, Heii, Ohkusa, Toshifumi, Sato, Nobuhiro |
| Source: |
Journal of Alzheimer's Disease; 2022, Vol. 88 Issue 1, p75-95, 21p |
| Subject Terms: |
CEREBRAL atrophy, OLDER patients, COGNITIVE ability, MILD cognitive impairment, PROBIOTICS, GUT microbiome, THERAPEUTIC use of probiotics, BRAIN, RESEARCH, RESEARCH methodology, COGNITION, EVALUATION research, ATROPHY, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment |
| Abstract: |
Background: Probiotics have been reported to ameliorate cognitive impairment.Objective: We investigated the effect of the probiotic strain Bifidobacterium breve MCC1274 (A1) in enhancing cognition and preventing brain atrophy of older patients with mild cognitive impairment (MCI).Methods: In this RCT, 130 patients aged from 65 to 88 years old with suspected MCI received once daily either probiotic (B. breve MCC1274, 2×1010 CFU) or placebo for 24 weeks. Cognitive functions were assessed by ADAS-Jcog and MMSE tests. Participants underwent MRI to determine brain atrophy changes using Voxel-based Specific Regional Analysis System for Alzheimer's disease (VSRAD). Fecal samples were collected for the analysis of gut microbiota composition.Results: Analysis was performed on 115 participants as the full analysis set (probiotic 55, placebo 60). ADAS-Jcog subscale "orientation" was significantly improved compared to placebo at 24 weeks. MMSE subscales "orientation in time" and "writing" were significantly improved compared to placebo in the lower baseline MMSE (< 25) subgroup at 24 weeks. VSRAD scores worsened in the placebo group; probiotic supplementation tended to suppress the progression, in particular among those subjects with progressed brain atrophy (VOI Z-score ≥1.0). There were no marked changes in the overall composition of the gut microbiota by the probiotic supplementation.Conclusion: Improvement of cognitive function was observed on some subscales scores only likely due to the lower sensitiveness of these tests for MCI subjects. Probiotics consumption for 24 weeks suppressed brain atrophy progression, suggesting that B. breve MCC1274 helps prevent cognitive impairment of MCI subjects. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Alzheimer's Disease is the property of IOS Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
